Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X, Friedlander S, Kupperman E, Sedarati F, Kuroda S, Hua Z, Yuan Y, Yamamoto Y, Faller DV, Haikawa K, Nakai K, Bowen S, Dai Y, Venkatakrishnan K. Zhou X, et al. Among authors: kupperman e. Clin Transl Sci. 2021 May;14(3):1069-1081. doi: 10.1111/cts.12972. Epub 2021 Feb 2. Clin Transl Sci. 2021. PMID: 33503305 Free PMC article. Clinical Trial.
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S. Lee EC, et al. Among authors: kupperman e. Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8. Clin Cancer Res. 2011. PMID: 21903769 Free PMC article.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J. Kupperman E, et al. Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16. Cancer Res. 2010. PMID: 20160034
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P, Monbaliu J, Fleming P, Dick L, Manfredi M, Claiborne C, Bolen J, Kupperman E, Berger A. Bannerman B, et al. Among authors: kupperman e. Cancer Chemother Pharmacol. 2011 Nov;68(5):1145-54. doi: 10.1007/s00280-011-1591-2. Epub 2011 Mar 13. Cancer Chemother Pharmacol. 2011. PMID: 21400028 Free PMC article.
Perspectives on molecular and anatomical imaging in drug discovery.
Silva MD, Johnson M, Cvet D, Robertson R, Kupperman E, Reimer C, Hibner B, Chandra S. Silva MD, et al. Among authors: kupperman e. Biotechniques. 2005 Dec;39(6 Suppl):S26-32. doi: 10.2144/000112092. Biotechniques. 2005. PMID: 20158501 Free article. Review. No abstract available.
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E. Hikichi Y, et al. Among authors: kupperman e. Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21. Mol Cancer Ther. 2012. PMID: 22188812
Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
Kuwabara S, Kusunoki S, Kuwahara M, Yamano Y, Nishida Y, Ishida H, Kasuya T, Kupperman E, Lin Q, Frick G, Misawa S. Kuwabara S, et al. Among authors: kupperman e. J Peripher Nerv Syst. 2024 Sep;29(3):339-349. doi: 10.1111/jns.12646. Epub 2024 Jul 10. J Peripher Nerv Syst. 2024. PMID: 38987228 Clinical Trial.
25 results